Continued EGFR Inhibition With Postprogression Chemotherapy: Where Do We Stand?
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA zpiotrowska@partners.org.
Zofia
Z
Piotrowska
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.
Lecia V
LV
Sequist
D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D066246:ErbB Receptors / Q000235:genetics*; D000069347:Erlotinib Hydrochloride / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage*
D047428:Protein Kinase Inhibitors; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors